scholarly journals Efficacy and toxicity of mitoxantrone and oral etoposide in the treatment of hormone-refractory prostate cancer: pilot study

2010 ◽  
Vol 8 (3) ◽  
pp. 336-338
Author(s):  
Rafael Kaliks ◽  
Camila Guerra ◽  
Auro Del Giglio
Keyword(s):  
Prostate Cancer ◽  
Pilot Study ◽  
Partial Response ◽  
Stable Disease ◽  
Response Rate ◽  
Response Duration ◽  
Oral Etoposide ◽  
Hormone Refractory Prostate Cancer ◽  
Toxicity Response ◽  
Hormone Refractory

ABSTRACT Objective: To evaluate the efficacy and toxicity of the association of mitoxantrone and oral etoposide. Methods: Twelve consecutive patients with metastatic hormone-refractory prostate cancer were treated with mitoxantrone and oral etoposide. Toxicity, response rate and response duration were assessed. Results: Partial response was observed in two patients (response duration of seven and four months) and one patient had stable disease (during four months). Mitoxantrone and oral Etoposide were well tolerated and did not affect tolerability to subsequent chemotherapy. Conclusion: Mitoxantrone and oral etoposide association is an active and well-tolerated regimen in hormone-refractory prostate cancer.

Lycopene for Advanced Hormone Refractory Prostate Cancer: A Prospective, Open Phase II Pilot Study

2009 ◽  
Vol 181 (3) ◽  
pp. 1098-1103 ◽  
Author(s):  
Carla Schwenke ◽  
Burkhard Ubrig ◽  
Petra Thürmann ◽  
Christian Eggersmann ◽  
Stephan Roth
Keyword(s):  
Prostate Cancer ◽  
Pilot Study ◽  
Phase Ii ◽  
Hormone Refractory Prostate Cancer ◽  
Open Phase ◽  
Hormone Refractory

scholarly journals Oral estramustine phosphate and oral etoposide for the treatment of hormone‐refractory prostate cancer

2000 ◽  
Vol 7 (7) ◽  
pp. 243-247 ◽  
Author(s):  
Yoshiteru Sumiyoshi ◽  
Katsuyoshi Hashine ◽  
Hironori Nakatsuzi ◽  
Yokihiko Yamashita ◽  
Takashi Karashima
Keyword(s):  
Prostate Cancer ◽  
Oral Etoposide ◽  
Hormone Refractory Prostate Cancer ◽  
Estramustine Phosphate ◽  
Hormone Refractory

Metronomic chemotherapy for hormone refractory prostate cancer (HRPC)

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 15649-15649
Author(s):  
S. Hoshi ◽  
K. Numahata ◽  
K. Hoshi ◽  
K. Suzuki ◽  
K. Ono ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Lymph Node ◽  
Bone Scan ◽  
Performance Status ◽  
Metronomic Chemotherapy ◽  
Response Duration ◽  
Complete Regression ◽  
Hormone Refractory Prostate Cancer ◽  
Median Response ◽  
Hormone Refractory

15649 Background: Low dose continuous chemotherapy (metronomic chemotherapy) is trying to many advanced cancers. Metronomic chemotherapy has important anti-angiogenic activity to tumor vessels. For patients who progressed after docetaxel, no standard options exist. We have experienced complete regression of bone metastases on super scan by low does cisplatin, UFT, diethylstilbestrol, and dexamethasone (CUDD) in a patient with HRPC (Int JCO, 8,118, 2003). Methods: CUDD consisting of weekly 5 mg/body of cisplatin plus 125 mg/body of diethylstilbestrol and daily 300–450 mg of UFT/day plus 0.5–1 mg of dexamethasone were given to 47 HRPC patients, (median and range of age: 66 and 52–72, respectively). The ECOG performance status was 0 to 1. Gleason score was 7 in 10 patients and 8 in 17 patients and 9 in 20 patients, respectively. Metastatic site was bone in 45 (EOD grade 1:10, 2:18, 3: 15, 4:2), lymph node in 8. Six cases became refractory to docetaxel were treated with CUDD plus CPM (50 mg/day). Results: Among the 45 patients assessable for bone metastasis, 12 (27 %) obtained marked improvement on bone scan. One was EOD grade 4 (super bone scan) and 9 were EOD grade 1–3. Eighteen (40 %) were stable and 15 (33%) progressed on bone scan. Among 8 patients of lymph node metastasis, 3 (38%) showed partial response, 2 (25%) no change and 3 (38%) progression. Twenty-five (53 %) out of 47 patients showed a PSA decline of 50% or greater. Among the 25 patients assessable for bone pain, 7 (28%) improved, 12 (48%) remained stable and 6 (24%) progressed. Their median response duration and median survival time were 8 months (range; 2 to 44 months) and 20 months (range, 4 to 48 months), respectively. Their median response duration was 3 months. Three of 6 refractory to docetaxel were responded to CUDD plus CPM. Their median response duration was 10 months. Conclusions: CUDD is effective in almost half of hormone refractory prostate cancer patients and has advantage of minimal side effect. Three of 6 docetaxel refractory cases also responded to CUDD plus CPM. No significant financial relationships to disclose.

Docetaxel-based chemotherapy as second-line treatment for paclitaxel-based chemotherapy-resistant hormone-refractory prostate cancer: A pilot study

Urology ◽  
2005 ◽  
Vol 65 (3) ◽  
pp. 543-548 ◽  
Author(s):  
Shinji Urakami ◽  
Tateki Yoshino ◽  
Nobuyuki Kikuno ◽  
Shin Imai ◽  
Satoshi Honda ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Pilot Study ◽  
Hormone Refractory Prostate Cancer ◽  
Line Treatment ◽  
Second Line ◽  
Hormone Refractory

Phase II Study of Estramustine, Oral Etoposide, and Vinorelbine in Hormone-Refractory Prostate Cancer

1997 ◽  
Vol 20 (4) ◽  
pp. 383-386 ◽  
Author(s):  
M. Colleoni ◽  
C. Graiff ◽  
G. Vicario ◽  
P. Nelli ◽  
G. Sgarbossa ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Phase Ii ◽  
Phase Ii Study ◽  
Oral Etoposide ◽  
Hormone Refractory Prostate Cancer ◽  
Hormone Refractory

Pilot Study of Oral Eniluracil/5-FU in the Palliation of Hormone-Refractory Prostate Cancer

2001 ◽  
Vol 3 (1) ◽  
pp. 30-35 ◽  
Author(s):  
Mark A. Rosenthal ◽  
David Thomas ◽  
Ian Davis ◽  
Guy Toner ◽  
Naeem Noordin ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Pilot Study ◽  
Hormone Refractory Prostate Cancer ◽  
Hormone Refractory

Weekly paclitaxel plus estramustine combination therapy in hormone-refractory prostate cancer: A pilot study

2003 ◽  
Vol 10 (9) ◽  
pp. 470-475 ◽  
Author(s):  
HIDETOSHI KURUMA ◽  
TETSUO FUJITA ◽  
TOSHIYA SHITARA ◽  
SHIN EGAWA ◽  
EIJI YOKOYAMA ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Pilot Study ◽  
Combination Therapy ◽  
Weekly Paclitaxel ◽  
Hormone Refractory Prostate Cancer ◽  
Hormone Refractory

Pilot Study of Rapamycin in Patients with Hormone-Refractory Prostate Cancer

2008 ◽  
Vol 6 (2) ◽  
pp. 97-102 ◽  
Author(s):  
Robert J. Amato ◽  
Jaroslaw Jac ◽  
Taqi Mohammad ◽  
Somya Saxena
Keyword(s):  
Prostate Cancer ◽  
Pilot Study ◽  
Hormone Refractory Prostate Cancer ◽  
Hormone Refractory

Prospective Randomized Study Comparing Docetaxel, Estramustine, and Prednisone With Docetaxel and Prednisone in Metastatic Hormone-Refractory Prostate Cancer

2008 ◽  
Vol 26 (32) ◽  
pp. 5261-5268 ◽  
Author(s):  
Jean-Pascal Machiels ◽  
Filomena Mazzeo ◽  
Marylene Clausse ◽  
Bertrand Filleul ◽  
Luc Marcelis ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Response Rate ◽  
Randomized Study ◽  
Specific Antigen ◽  
Hormone Refractory Prostate Cancer ◽  
Serious Adverse Events ◽  
Psa Response ◽  
Psa Progression ◽  
Hormone Refractory ◽  
Grade 3

PurposeTo assess the efficacy and toxicity of the addition of estramustine to docetaxel (D) for the treatment of metastatic hormone-refractory prostate cancer.Patients and MethodsOne hundred fifty patients were randomly assigned to D alone (35 mg/m2on days 2 and 9, every 3 weeks) or D in combination with estramustine (D/E; 280 mg orally three times a day on days 1 to 5 and 8 to 12, every 3 weeks). All patients received prednisone (10 mg/d). The primary end point was prostate-specific antigen (PSA) response rate, which was defined as a decrease in PSA ≥ 50% from baseline. The study was powered to test the hypothesis that D/E would improve the PSA response rate by 25%.ResultsThe PSA response rate was not statistically different between the two groups. PSA of less than 4 ng/mL occurred in 29 (41%) of 71 patients receiving D/E and in 17 (25%) of 69 patients receiving D (P = .05). No significant differences were found for median time to PSA progression (D/E, 6.9 months; D, 7.3 months) or median overall survival time (D/E, 19.3 months; D, 21 months). More patients had at least one grade 3 or 4 toxicity with D/E (45%) compared with D (21%; P = .005), mainly as a result of grade 3 or 4 GI toxicity (P = .05). Serious adverse events were more frequent with D/E (n = 20) than with D (n = 9; P = .04).ConclusionThe addition of estramustine to weekly D does not provide any clinically relevant advantage. Both regimens are well tolerated, although the toxicity profile favors D without estramustine.

Sign in / Sign up

Export Citation Format

Share Document